



An Examination of How Set & Setting Facilitate Peak-Experiences

Bibliography:

1

- St John Sessa, B. (2008). Are psychedelic drug treatments seeing a comeback in psychiatry? *Progress in Neurology and Psychiatry*, 12(8), 5-10.

2

- Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P. C. R., & Strassman, R. J. (2015). Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study. *Journal of Psychopharmacology*, 29(3), 289-299.

3

- Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-HT_{2A}R agonist psilocybin in the treatment of tobacco addiction. *Journal of Psychopharmacology*, 0269881114548296.

4

- Carhart-Harris, R., Bolstridge, M., Rucker, J., Day, C., Erritzoe, D., Kaelen, M., Bloomfield, M., Rickard, J., Forbes, B., Feilding, A., Taylor, D., Pilling, S., Curran, V. and Nutt, D. (2016). Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *The Lancet Psychiatry*, 3(7), pp.619-627.

5

- Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B.D., Klinedinst, M. A. (2016). Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. *Journal of psychopharmacology (Oxford, England)*, 30(12), 1181.
- Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., . . . Babb, J. (2016). Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. *Journal of psychopharmacology (Oxford, England)*, 30(12), 1165.

6

- Mithoefer, M., Mithoefer, A., Feduccia, A., Jerome, L., Wagner, M., Wymer, J., Holland, J., Hamilton, S., Yazar-Klosinski, B., Emerson, A. and Doblin, R. (2018). 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial. *The Lancet Psychiatry*, 5(6), pp.486-497.

7

- Garcia-Romeu, A., R Griffiths, R., & ;W Johnson, M. (2014). Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction. *Current drug abuse reviews*, 7(3), 157-164.
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & ;Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology*, 218(4), 649-665.
- Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & ;Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *Journal of Psychopharmacology*.
- Griffiths, R. R., Richards, W. A., McCann, U., & ;Jesse, R. (2006). Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. *Psychopharmacology*, 187(3), 268-283.
- Soler, J., Elices, M., Franquesa, A., Barker, S., Friedlander, P., Feilding, A., . . . Riba, J. (2016). Exploring the therapeutic potential of Ayahuasca: acute intake increases mindfulness-related capacities. *PSYCHOPHARMACOLOGY -BERLIN-*, 233(5), 823-829.
- Thomas, G., Lucas, P., Capler, N. R., Tupper, K. W., & ;Martin, G. (2013). Ayahuasca-assisted therapy for addiction: Results from a preliminary observational study in Canada. *Curr Drug Abuse Rev*, 6(1), 30-42.
- MacLean, K. A., Johnson, M. W., & ;Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *Journal of Psychopharmacology*, 25(11), 1453-1461.

8

Kotler, S. (2014). *The Rise of Superman: Decoding the Science of Ultimate Human Performance*. 1st ed. New Harvest.

9

- Csikszentmihalyi, M., Rathunde, K., & Whalen, S. (1993). *Talented teenagers: A longitudinal study of their development*. New York: Cambridge University Press.
- Jackson, S. A., Ford, S. K., Kimiecik, J. C., and Marsh, H. W. (1998). Psychological correlates of flow in sport. *J. Sport Exerc. Psychol.* 20, 358–378. doi: 10.1123/jsep.20.4.358
- Carli, M., Fave, A. D., and Massimini, F. (1988). *The Quality of Experience in the Flow Channels: Comparison of Italian and US students*. New York, NY: Cambridge University Press.
- Nakamura, J. (1988). "Optimal experience and the uses of talent," in *Optimal Experience: Psychological Studies of Flow in Consciousness*, eds M. Csikszentmihalyi, and I. S. Csikszentmihalyi (New York, NY: Cambridge University Press), 319–326.
- Jackson, S. A., Thomas, P. R., Marsh, H. W., and Smethurst, C. J. (2001). Relationships between flow, self-concept, psychological skills, and performance. *J. Appl. Sport Psychol.* 13, 129–153. doi: 10.1080/104132001753149865
- MacDonald, R., Byrne, C., and Carlton, L. (2006). Creativity and flow in musical composition: an empirical investigation. *Psychol. Music.* 34, 292–306. doi: 10.1177/0305735606064838
- Csikszentmihalyi, M. (1988). "The Flow experience and its significance for human psychology," in *Optimal Experience: Psychological Studies of Flow in Consciousness*, eds M. Csikszentmihalyi and I. S. Csikszentmihalyi (Cambridge: Cambridge University Press), 15–35.

10

- Griffiths, R. R., Richards, W. A., Johnson, M. W., McCann, U. D., & Jesse, R. (2008). Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. *Journal of Psychopharmacology*.
- MacLean, K. A., Johnson, M. W., & Griffiths, R. R. (2011). Mystical experiences occasioned by the hallucinogen psilocybin lead to increases in the personality domain of openness. *Journal of Psychopharmacology*, 25(11), 1453-1461.

11

- Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When and how do therapeutic effects of hallucinogens depend on

psychedelic experiences? *Journal of Psychopharmacology*, 29(3), 241–253.
<https://doi.org/10.1177/0269881114568040>

- Maslow, A. H. (1961). Peak experiences as acute identity experiences. *The American Journal of Psychoanalysis*, 21(2), 254–262. <https://doi.org/10.1007/BF01873126>
- Maslow, A. H. (1965). Religions, Values, and Peak-Experiences. *Journal for the Scientific Study of Religion*, 5, 179. <https://doi.org/10.2307/1384286>
- Carhart-Harris, R. L., Kaelen, M., Bolstridge, M., Williams, T. M., Williams, L. T., Underwood, R., . . . Nutt, D. J. (2016). The paradoxical psychological effects of lysergic acid diethylamide (LSD). *Psychological medicine*, 46(7), 1379-1390.
- Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., McCann, U., & Jesse, R. (2011). Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects. *Psychopharmacology*, 218(4), 649-665.
- Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011). Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Archives of general psychiatry*, 68(1), 71-78.
- Studerus, E., Komater, M., Hasler, F., & Vollenweider, F. X. (2011). Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *Journal of Psychopharmacology*, 25(11), 1434-1452.

12

- Kotler, S. and Wheel, J. (2017). *Stealing Fire: How Silicon Valley, the Navy SEALs, and Maverick Scientists Are Revolutionizing the Way We Live and Work*. 1st ed. Dey Street Books.

13

- Leary, T., Litwin, G. H., & Metzner, R. (1963). Reactions to Psilocybin Administered in a Supportive Environment. *The Journal of nervous and mental disease*, 137(6), 561-573.